

Xavier Garcia-Moll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1359266/publications.pdf>

Version: 2024-02-01

46
papers

1,271
citations

361413

20
h-index

361022

35
g-index

58
all docs

58
docs citations

58
times ranked

1809
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of medical management in Coronary Type 2 Diabetic patients with previous percutaneous coronary intervention in Spain: A retrospective analysis of electronic health records using Natural Language Processing. PLoS ONE, 2022, 17, e0263277.	2.5	9
2	Urinary Proteomic Signature in Acute Decompensated Heart Failure: Advances into Molecular Pathophysiology. International Journal of Molecular Sciences, 2022, 23, 2344.	4.1	3
3	Differentiation of athlete's heart and hypertrophic cardiomyopathy by the fractal dimension of left ventricular trabeculae. International Journal of Cardiology, 2021, 330, 232-237.	1.7	3
4	Moving from the stratification of primary and secondary prevention of cardiovascular risk in diabetes towards a continuum of risk: need for a new paradigm. Drugs in Context, 2021, 10, 1-3.	2.2	3
5	The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 883-891.	1.5	30
6	Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry. Journal of Clinical Medicine, 2020, 9, 4.	2.4	17
7	Incidence and costs of cardiovascular events in Spanish patients with type 2 diabetes mellitus: a comparison with general population, 2015. BMJ Open Diabetes Research and Care, 2020, 8, e001130.	2.8	8
8	Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial. Drugs in Context, 2020, 9, 1-15.	2.2	3
9	Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition. Expert Review of Clinical Pharmacology, 2020, 13, 695-706.	3.1	4
10	Role of rivaroxaban in the prevention of atherosclerotic events. Expert Review of Clinical Pharmacology, 2019, 12, 771-780.	3.1	12
11	Obesity and prognosis: Time to forget about metabolically healthy obesity. European Heart Journal, 2018, 39, 407-409.	2.2	17
12	Rivaroxaban: searching the integral vascular protection. Expert Review of Clinical Pharmacology, 2018, 11, 719-728.	3.1	11
13	Lack of relationship between plasma levels of escitalopram and QTc-interval length. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 815-822.	3.2	7
14	On Contrast-Induced Acute Kidney Injury, Risk Prediction, and the Future of Predictive Model Development. Canadian Journal of Cardiology, 2017, 33, 711-713.	1.7	4
15	Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the <sc>EPICOR</sc> study. Cardiovascular Therapeutics, 2017, 35, e12237.	2.5	6
16	Letter by Garcia-Moll Regarding Article, "Glycemic Control Status After Percutaneous Coronary Intervention and Long-Term Clinical Outcomes in Patients With Type 2 Diabetes Mellitus": Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	0
17	Lights and (Some) Shadows in the Management of Acute Coronary Syndrome in Spain: the DIOCLES Study. Revista Espanola De Cardiologia (English Ed), 2015, 68, 85-86.	0.6	0
18	Luces y (algunas) sombras en el manejo del sÃndrome coronario agudo en EspaÃa: el estudio DIOCLES. Revista Espanola De Cardiologia, 2015, 68, 85-86.	1.2	1

#	ARTICLE	IF	CITATIONS
19	Feasibility and Safety of an Early Discharge Strategy after Low-Risk Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: The EDAMI Pilot Trial. <i>Cardiology</i> , 2015, 130, 120-129.	1.4	33
20	Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications. , 2015, , 187-235.		0
21	Selected CD133 ⁺ Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina. <i>Circulation Research</i> , 2014, 115, 950-960.	4.5	63
22	Impact of Chronic Kidney Disease on Use of Evidence-Based Therapy in Stable Coronary Artery Disease: A Prospective Analysis of 22,272 Patients. <i>PLoS ONE</i> , 2014, 9, e102335.	2.5	21
23	Demographic and Clinical Characteristics of Patients With Stable Coronary Artery Disease: Results From the CLARIFY Registry in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 538-544.	0.6	12
24	Validation of a New Risk Score to Predict Contrast-Induced Nephropathy After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1487-1493.	1.6	39
25	Citalopram, escitalopram and prolonged QT: Warning or alarm?. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2014, 7, 147-150.	0.3	3
26	Caracter�sticas demogr�ficas y cl�nicas de los pacientes con enfermedad coronaria estable: resultados del registro CLARIFY en Espa�a. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 538-544.	1.2	18
27	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.2	83
28	Estudio de la angina estable en Espa�a y su impacto en la calidad de vida del paciente. Registro AVANCE. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 734-741.	1.2	32
29	Caso cl�nico 2: paciente con angina cr�nica estable y varios factores de riesgo. Diagn�stico, estratificaci�n pron�stica y tratamiento. <i>Revista Espanola De Cardiologia Suplementos</i> , 2012, 12, 30-36.	0.2	2
30	Comentarios a la gu�a de pr�ctica cl�nica de la ESC para el manejo del s�ndrome coronario agudo en pacientes sin elevaci�n persistente del segmento ST. Un informe del Grupo de Trabajo del Comit� de Gu�as de Pr�ctica Cl�nica de la Sociedad Espa�ola de Cardiolog�a. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 125-130.	1.2	21
31	Proteomic Signature of Apolipoprotein J in the Early Phase of New-Onset Myocardial Infarction. <i>Journal of Proteome Research</i> , 2011, 10, 211-220.	3.7	61
32	Serum proteome in acute myocardial infarction. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2011, 23, 147-154.	0.8	3
33	Vitamin B12 deficiency, hyperhomocysteinemia and thrombosis: a case and control study. <i>International Journal of Hematology</i> , 2011, 93, 458-464.	1.6	55
34	Interferencias por contrastes yodados en la electroforesis capilar. <i>Revista Del Laboratorio Cl�nico</i> , 2010, 3, 129-135.	0.1	1
35	A comparative study of biomarkers for risk prediction in acute coronary syndrome��Results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. <i>Atherosclerosis</i> , 2010, 212, 636-643.	0.8	47
36	New electrocardiographic diagnostic criteria for the pathologic R waves in leads V1 and V2 of anatomically lateral myocardial infarction. <i>Journal of Electrocardiology</i> , 2008, 41, 413-418.	0.9	29

#	ARTICLE	IF	CITATIONS
37	Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. <i>Atherosclerosis</i> , 2008, 201, 176-183.	0.8	45
38	Concordance of Electrocardiographic Patterns and Healed Myocardial Infarction Location Detected by Cardiovascular Magnetic Resonance. <i>American Journal of Cardiology</i> , 2006, 97, 443-451.	1.6	77
39	Utility of Contrast-Enhanced Cardiovascular Magnetic Resonance (CE-CMR) to Assess How Likely is an Infarct to Produce a Typical ECG Pattern. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2006, 8, 335-344.	3.3	42
40	Fisiopatología y marcadores del síndrome coronario agudo sin elevación del segmento ST. <i>Revista Española De Cardiología Suplementos</i> , 2005, 5, 8C-14C.	0.2	2
41	Ejemplos de intervenciones para mejorar la calidad de la atención al síndrome coronario agudo sin elevación del segmento ST. <i>Revista Española De Cardiología Suplementos</i> , 2005, 5, 47C-52C.	0.2	0
42	Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. <i>European Heart Journal</i> , 2001, 22, 1578-1584.	2.2	41
43	Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. <i>American Journal of Cardiology</i> , 2000, 86, 449-451.	1.6	125
44	C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. <i>European Heart Journal</i> , 2000, 21, 1598-1606.	2.2	54
45	Serum neopterin and complex stenosis morphology in patients with unstable angina. <i>Journal of the American College of Cardiology</i> , 2000, 35, 956-962.	2.8	111
46	Prospective study of bacteremia during transesophageal echocardiography. <i>American Heart Journal</i> , 1993, 125, 1454-1455.	2.7	9